Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01979523 · ClinicalTrials.gov registry record · Phase 2
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
A Phase 2 study of Stage IV Uveal Melanoma AJCC v7 and Recurrent Uveal Melanoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 7
- Study locations
NCT01979523 is a Phase 2 study of Stage IV Uveal Melanoma AJCC v7 and Recurrent Uveal Melanoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 42 participants. The trial reports 7 study locations across 5 states.
The verdict
NCT01979523, a Phase 2 study of Stage IV Uveal Melanoma AJCC v7 and Recurrent Uveal Melanoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 7
- Study locations
Study Summary
This randomized phase II trial studies how well trametinib with or without Akt inhibitor GSK2141795 (GSK2141795) works in treating patients with uveal melanoma that has spread to other parts of the body (metastatic). Trametinib and GSK2141795 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether trametinib is more effective with or without GSK2141795 in treating patients with metastatic uveal melanoma.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Trametinib
- OTHER Pharmacological Study
- DRUG Uprosertib
Study Locations (7)
New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Other
- Institut Curie Paris - Paris
- The University of Liverpool - Liverpool
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
Tennessee
- Vanderbilt University/Ingram Cancer Center - Nashville
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2013-11-21 |
| Est. Completion | 2026-07-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01979523
The ClinicalTrials.gov registry entry for NCT01979523 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Stage IV Uveal Melanoma AJCC v7 appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01979523 reports 7 study locations spanning 5 distinct geographic areas - top geographies include New York, Other, Georgia.
Frequently Asked Questions
What is clinical trial NCT01979523 about?
NCT01979523 is a clinical study titled "Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma". This randomized phase II trial studies how well trametinib with or without Akt inhibitor GSK2141795 (GSK2141795) works in treating patients with uveal melanoma that has spread to other parts of the body (metastatic). Trametinib and GSK2141795 may stop the growth of tumor cells by blocking some of th...
What is the current status of trial NCT01979523?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2013-11-21. Estimated completion is 2026-07-02.
What conditions does trial NCT01979523 study?
This clinical trial studies the following conditions: Stage IV Uveal Melanoma AJCC v7, Recurrent Uveal Melanoma.
What interventions are being tested in trial NCT01979523?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Trametinib (DRUG), Pharmacological Study (OTHER), Uprosertib (DRUG).
Who is sponsoring clinical trial NCT01979523?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01979523 being conducted?
This trial has 7 study locations across Georgia, New York, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Uveal Melanoma AJCC v7
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.